U.S. Residential REITs Stock News

If you are wondering whether Tilray Brands' share price reflects its true worth, it helps to step back and look at how the market has treated the stock over different time frames. The share price last closed at US$7.92, with a 5.5% gain over the past 7 days, a 12.5% decline over 30 days, an 18.5% decline year to date and a 1.9% decline over the past year, alongside a much larger 72.0% decline across three years. Recent attention on cannabis policy and sector sentiment has kept Tilray Brands...

In February 2026, Herbalife Ltd. reported fourth-quarter 2025 sales of US$1,283.0 million and net income of US$85.4 million, issued 2026 net sales growth guidance, and announced plans to refinance up to US$1.55 billion of senior secured debt to extend its maturity profile. At the same time, Herbalife highlighted its push into personalized nutrition and digital health through its Pro2col platform, supported by a US$7.5 million investment and services commitment from Cristiano Ronaldo for a...

If you are wondering whether Teleflex is starting to look like value after a tough few years, this article will walk through what the current share price might be implying. The stock has risen 5.9% over the last 7 days and 8.4% over the last 30 days, although it remains down 8.4% year to date and 36.2% over 1 year, with a 51.8% 3 year and 71.3% 5 year decline. Recent coverage of Teleflex has largely focused on how the share price has pulled back over several years and what that means for...

If you are wondering whether Eli Lilly's current share price fairly reflects its long term potential, you are not alone. This article is designed to help you make sense of what you are paying for. The stock last closed at US$1,042.15, with returns of 0.6% over 7 days, a 2.1% decline over 30 days, a 3.5% decline year to date, and a 16.4% gain over the past year. The 3 year return sits at 242.4% and the 5 year return at 436.6%. Recent headlines around Eli Lilly have focused on its role in...

Oncolytics Biotech (ONCY) has attracted fresh attention after a recent move in its share price, with the stock closing at US$1.13 and showing mixed return patterns across the past year and over multiple years. See our latest analysis for Oncolytics Biotech. The recent 6.6% 1 day share price return and 10.8% 7 day share price return suggest short term momentum is building around Oncolytics Biotech, even as the 58.3% 1 year total shareholder return contrasts with weaker 3 and 5 year total...

New global tariffs announced by the Trump administration and weaker recent financial updates have put Crocs (CROX) in focus, as investors reconsider the stock in light of softer guidance and pressure on internationally reliant supply chains. See our latest analysis for Crocs. The mixed backdrop of tariff headlines, softer guidance and ongoing buybacks has coincided with a 12.65% 1 month share price return and 13.14% 3 month share price return. However, the 1 year total shareholder return of...

Preferred Bank reclassified a sizable loan relationship from substandard to nonaccrual status following ongoing legal complications involving the borrower’s principals. The borrower is facing complex lawsuits that have contributed to cash flow pressures and payment issues on the loan. Management has indicated that, based on current expectations, the ultimate resolution of this credit is not expected to significantly affect 2026 earnings. For you as an investor following NasdaqGS:PFBC, this...

Boise Cascade (BCC) has wrapped up FY 2025 with Q4 revenue of US$1.5 billion and basic EPS of US$0.24, alongside trailing twelve month revenue of US$6.4 billion and EPS of US$3.54 that frame the current run rate. The company has seen quarterly revenue range from US$1.5 billion to US$1.7 billion across 2025, with basic EPS moving from US$1.06 in Q1 and US$1.64 in Q2 to US$0.58 in Q3 and US$0.24 in Q4. This puts the spotlight squarely on how sustainably Boise Cascade can defend its margins from...

If you are wondering whether Generac Holdings at around US$235 per share is still reasonably priced or already stretched, you are not alone. The stock has returned 0.7% over the last 7 days, 35.9% over 30 days, 66.7% year to date, 69.5% over 1 year and 96.0% over 3 years, while the 5 year return sits at a 30.6% decline. These moves have come as investors continue to reassess Generac's role in the capital goods space. They are paying close attention to how its products fit into longer term...

Earlier in February 2026, Impinj reported its fourth-quarter and full-year 2025 results, highlighting record adjusted EBITDA margins and a 9% year-over-year increase in endpoint IC unit volumes driven by its M800 platform, while guiding first-quarter 2026 revenue to be roughly 2% lower year-over-year amid inventory normalization, retail softness, product obsolescence, and modest price reductions. Analyst commentary following these results, including concerns about extended channel inventory...

Curbline Properties Corp., a self-managed REIT trading under the symbol CURB, recently declared its first quarter 2026 common stock dividend of US$0.17 per share, a 6% increase from the fourth quarter 2025 payout, payable on April 8, 2026 to shareholders of record on March 18, 2026. This higher dividend highlights management’s willingness to return more cash to investors, which may be interpreted as confidence in the REIT’s ability to support its current payout level. We’ll now examine how...

CoreCivic (CXW) is back on investor radars after recent share price swings, with the stock up about 1.6% on the day but showing declines over the past week and month. See our latest analysis for CoreCivic. While the share price is around $16.47 today and up on the day, the 7 day and 30 day share price returns of 11.88% and 17.94% declines contrast with a much stronger 3 year and 5 year total shareholder return of 69.62% and 121.97%. This suggests longer term holders have seen very different...

Skyward Specialty Insurance Group (SKWD) closed out FY 2025 with fourth quarter revenue of US$385.6 million and basic EPS of US$1.07, while trailing twelve month revenue reached about US$1.4 billion and EPS came in at US$4.21. The company reported revenue increasing from US$304.4 million in Q4 2024 to US$385.6 million in Q4 2025, with basic EPS rising from US$0.36 to US$1.07 over the same period. These figures frame a situation in which investors may compare the company’s earnings power with...

Enterprise Products Partners (NYSE:EPD) has been actively presenting at major energy conferences and holding meetings with investors. Company materials highlight an outlook for double digit growth in 2027 tied to new assets and projected natural gas demand. Management is framing AI data centers and other technology related users as a potential source of future natural gas consumption. For income focused investors, NYSE:EPD sits at the intersection of large scale midstream infrastructure and...

Earlier this month, Bio-Techne announced that its Ella benchtop immunoassay platform received CE-IVD marking, clearing the way for clinical use across the European Union and enabling hospitals and laboratories to deploy the system for in-house test development, clinical trials, and broader translational activities. This certification extends Ella beyond research labs into regulated clinical workflows, strengthening Bio-Techne’s role in standardized biomarker detection and precision medicine...

Broadridge Financial Solutions recently appointed Frank Troise as President, Global Capital Markets, elevating him to the Executive Leadership Team under Global Technology & Operations leader Tom Carey. Troise’s track record in trading technology and tokenized real assets positions Broadridge to further integrate AI-powered capabilities into its global capital markets offering. We’ll now explore how Troise’s expanded capital markets remit could influence Broadridge’s investment narrative...

What the recent performance says about Farmers & Merchants Bank of Long Beach (FMBL) Farmers & Merchants Bank of Long Beach (FMBL) has quietly posted positive returns over several time frames, including the past week, month and past 3 months, alongside a 1 year total return above 50%. For a thinly traded regional bank founded in 1907 and focused on Southern California customers, these moves give you a reason to look more closely at how its current share price lines up with recent business...

Fortune Brands Innovations recently announced a leadership shake-up, with long-time director Amit Banati set to become CEO in May 2026 after Nicholas Fink’s departure, while Chair Susan Kilsby temporarily assumes Executive Chair and interim CEO duties during the transition. This leadership change comes as activist investor Ed Garden pushes for board and management adjustments and the company reports lower 2025 sales of US$4.46 billion and net income of US$298.8 million, alongside new 2026...

Why Marsh & McLennan Companies (MRSH) is on investors’ radar today Marsh & McLennan Companies (MRSH) has been drawing fresh attention after recent share performance left the stock down over the past year and in the red year to date, prompting investors to reassess its current pricing and long term track record. See our latest analysis for Marsh & McLennan Companies. Recent trading has been mixed, with a 1 day share price return of 0.81% and a 7 day share price return of 1.48% contrasting with...

In February 2026, Gates Industrial Corporation plc reported higher fourth-quarter and full-year 2025 sales and net income, introduced 2026 core sales growth guidance, and confirmed completion of share repurchases totaling 13,041,187 shares for roughly US$243.63 million under two buyback authorizations. The combination of improving earnings, explicit 2026 growth targets, and sizeable completed buybacks signals management’s focus on enhancing per-share performance and capital returns. With...

In February 2026, PTC Therapeutics reported fourth-quarter 2025 results showing revenue of US$164.68 million versus US$213.17 million a year earlier, alongside a wider quarterly net loss, while full-year 2025 revenue rose to US$1.73 billion and net income reached US$682.64 million compared with a net loss previously. A key development was PTC’s withdrawal of its Translarna NDA resubmission for nonsense mutation Duchenne muscular dystrophy in the U.S. after FDA feedback, introducing fresh...

If you are wondering whether Rollins at around US$60.51 is still a solid pick or starting to look stretched, you are not alone in questioning what you are really paying for here. The share price has seen mixed moves recently, with a 0.7% return over the last 7 days, a 3.8% decline over 30 days, a 2.5% return year to date, and a 19.2% return over 1 year, while the 3 year and 5 year returns sit at 78.7% and 92.5% respectively. Those returns have kept Rollins on many investors' watchlists, and...

MicroVision (MVIS) has drawn fresh attention after outlining a business update and fireside chat on its lidar plans, alongside new zero coupon convertible note offerings and an exchange offer tied to 2028 maturities. See our latest analysis for MicroVision. The recent 8.78% 1 day share price return to US$0.8721 and 15.48% 7 day share price return suggest short term momentum has picked up. However, the 1 year total shareholder return of 33.43% and 5 year total shareholder return of 94.85%...

Sphere Entertainment Co. recently reported its fourth-quarter and full-year 2025 results, with quarterly sales of US$394.28 million and net income of US$64.74 million, and full-year sales of US$1.22 billion alongside net income of US$33.41 million, marking a move to profitability versus losses a year earlier. The earnings release highlighted a sharp improvement in earnings per share from continuing operations, with diluted EPS turning from a loss of US$9.77 to a profit of US$0.74 for the...